Alexandr Poprach

How modern therapies dislodged chemotherapy in advanced urothelial carcinoma

We keep rediscovering the same truth—hormonal biology works. Estrogen returns in prostate cancer, this time via patches, with noninferior outcomes and potentially better tolerability. Not new—just better applied. Study in @NEJM by the #Stampede group/@MRCCTU nejm.org/doi/full/10.10…

Doc. @RadkaObermanno1 se aktivně účastnila Evropské konference pro nemoci jícnu #ESDE2026 a představila data z národní platformy #GENESIS věnované precizní onkologii, zahrnující soubor více než 2200 pacientů.

Pleased to share that the 2026 @NCCN Bladder Cancer Guidelines now incorporate the @IBCG_BladderCa risk stratification framework for intermediate-risk NMIBC. A milestone reflecting more than a decade of collaborative work by colleagues worldwide einpresswire.com/article/901009… @UrogerliMD @drtanws @shilpaonc @pjhensley11 @mouwlab @AndreaNecchi @LAUrology_NL @AmirHorowitz @karima_oualla @PGrivasMDPhD @paolo_gontero @pcvblack @MaxKates @SpiessPhilippe @RobertoContieri @KKBree @LauraBukavinaMD @MRoupret @joanfundi @UroToday @BladderCancerUS @WorldBladderCan

TALAPRO-3 trial shows improvement in rPFS for HRR gene-mutated mHSPC. Together with the recent AMPLITUDE data, reinforces the role of HRR testing in these patients.

#SESAUA26 State of the Art Lecture @sanojpunnen PCa Screening Guidelines: ♦️Start: 45-50 yrs ♦️Screen q2-4 yrs if PSA < 1 ♦️Screen q1-2 yrs if PSA >1 ♦️Intervene: PSA 3-4 ♦️Stop: 70-75 yrs or life expectancy < 10 yrs @urotoday

Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose Chemotherapy | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Zveme onkologické pacienty k účasti na studii s vysoce inovativní metodou léčby deprese s pomoci psychedelik. Studie je určena pro pacienty s depresí bez ohledu na fázi onemocnění a léčby i pro vyléčené pacienty v dispenzární péči. mou.cz/onkologicti-pa… 👈

@tompowles1 @weoncologists @Uromigos @kalasri3 Thanks for the shoutout Tom. We need to help our patients and deliver a unified message: The OS advantage seen with EV+P relies on consolidation with Radical Cystectomy + PLND (not observation, not TMT) #EAU26

Time-of-day administration of ICI matters in metastatic #kidneycancer just presented at #EAU26 thanks to @YujiMiura5 @DrDanielHeng and other collaborators Results from an ongoing prospective trial are eagerly anticipated @BCCancer_Agency @Uroweb @OncoAlert urosource.uroweb.org/267359/abstract

Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study - The Lancet Oncology thelancet.com/journals/lanon…

Head-to-head comparison of pembrolizumab + axitinib vs pembrolizumab + lenvatinib in metastatic RCC: real-world data from the Canadian Kidney Cancer Information System database. Presented by @AlexFaco93 @mcgillu. #GU26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/47aeVQz @ASCO

⚠️ RT + Targeted Therapy = Hidden Toxicity Risk? New ESMO–ESTRO consensus on combining radiotherapy with: 🔹 EGFR inhibitors 🔹 ALK inhibitors 🔹 BRAF/MEK inhibitors 📄 Review in ESMO Open 2026 🟣 EGFR inhibitors • ↑ Dermatitis & mucositis risk • Thoracic RT + osimertinib → high pneumonitis risk • Major adaptation recommended in most high-dose settings 🔵 ALK inhibitors • Evidence limited • Most scenarios → major adaptation advised • CNS combinations need caution 🔴 BRAF/MEK inhibitors • Clear ↑ skin toxicity • High-dose skin RT → avoid combination • Vemurafenib + skin RT → do NOT combine @OncoAlert @myESMO @ASCO

Combination therapy is emerging as a standard in refractory RCC. Combos increase tumor shrinkage endpoints. TKI provides early disease control. CRs are possible but is cure? Toxicity consideration is critical in this setting. Biomarkers to guide choice of drug(s) are needed

Initial results from CLIMATE, a prospective cohort study assessing the clinical utility of miR-371a-3p (miR-371) as a marker of minimal residual disease (MRD) in clinical stage 1 testicular germ cell tumour (TGCT): ANZUP 1906. #GU26

Gemcitabine intravesical system (Gem-iDRS) in combination with cetrelimab (CET) versus chemoradiotherapy (CRT) in muscle-invasive bladder cancer (MIBC): SunRISe-2 final results. #GU26

28. 2. je Den vzácných onemocnění #RareDiseaseDay Vzácná nádorová onemocnění se vyskytují u méně než 6 pacientů ze 100 000 za rok. MOÚ má nejen Centrum pro nádory neznámého původu a jiné vzácné malignity, ale je také členem sítě @ERN_EURACAN sdružující odborníky z celé Evropy.

Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study. #GU26

Treatment selection in mHSPC, amazing talk by @ChrisSweens1 #GU26

It is worth pursuing anti-angiogenesis in refractory GCT | our PAZOTEST trial followed a similar line. @Annals_Oncology Time for a randomized trial? Congratulations @IndianaUniv @Dr_Lawrences @nabiladra & team sciencedirect.com/science/articl…